Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

NCT05433532 ·Status: COMPLETED ·Phase: PHASE2

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT05687032 ·Status: COMPLETED ·Phase: PHASE4

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

NCT05782127 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Safety Assessment of a Multipeptide-gene Vaccine in CML

NCT00455221 ·Status: COMPLETED ·Phase: PHASE1

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

NCT05197426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT05029141 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

NCT05141682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

NCT01757535 ·Status: COMPLETED ·Phase: PHASE3

Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)

NCT06326697 ·Status: COMPLETED ·Phase: PHASE1

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

NCT04795427 ·Status: COMPLETED ·Phase: PHASE2

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

NCT06180863 ·Status: WITHDRAWN ·Phase: PHASE2

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

NCT04722952 ·Status: UNKNOWN ·Phase: PHASE3

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

NCT03980002 ·Status: RECRUITING ·Phase: PHASE2

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

NCT00237120 ·Status: COMPLETED ·Phase: PHASE3

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

NCT07454226 ·Status: RECRUITING ·Phase: NA

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

NCT02954653 ·Status: TERMINATED ·Phase: PHASE1

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

NCT00890929 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02899286 ·Status: UNKNOWN ·Phase: PHASE2

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

NCT03932331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

NCT06647862 ·Status: RECRUITING ·Phase: PHASE3

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

NCT06054113 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

NCT00989261 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT06817720 ·Status: RECRUITING ·Phase: PHASE2

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

NCT05311943 ·Status: UNKNOWN ·Phase: PHASE3